A detailed history of Silverarc Capital Management, LLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Silverarc Capital Management, LLC holds 2,968,798 shares of MRSN stock, worth $5.97 Million. This represents 4.46% of its overall portfolio holdings.

Number of Shares
2,968,798
Previous 301,600 884.35%
Holding current value
$5.97 Million
Previous $699,000 1802.72%
% of portfolio
4.46%
Previous 0.22%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$2.16 - $5.94 $7.45 Million - $20.5 Million
-3,451,338 Reduced 53.76%
2,968,798 $13.3 Million
Q4 2023

Feb 14, 2024

BUY
$1.11 - $2.34 $1.58 Million - $3.32 Million
1,420,136 Added 28.4%
6,420,136 $14.9 Million
Q3 2023

Nov 13, 2023

BUY
$1.06 - $3.91 $4.24 Million - $15.6 Million
4,000,000 Added 400.0%
5,000,000 $6.35 Million
Q2 2023

Aug 14, 2023

BUY
$3.08 - $9.55 $1.42 Million - $4.39 Million
459,941 Added 85.16%
1,000,000 $3.29 Million
Q1 2023

May 15, 2023

SELL
$4.0 - $7.02 $2.4 Million - $4.21 Million
-600,123 Reduced 52.63%
540,059 $2.22 Million
Q4 2022

Feb 14, 2023

BUY
$5.65 - $7.86 $825,515 - $1.15 Million
146,109 Added 14.7%
1,140,182 $6.68 Million
Q3 2022

Oct 28, 2022

BUY
$4.63 - $8.0 $667,057 - $1.15 Million
144,073 Added 16.95%
994,073 $6.72 Million
Q2 2022

Jul 25, 2022

BUY
$2.84 - $5.0 $2.41 Million - $4.25 Million
850,000 New
850,000 $3.93 Million
Q3 2021

Nov 15, 2021

SELL
$8.56 - $14.47 $1.07 Million - $1.81 Million
-125,123 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$13.28 - $18.07 $1.33 Million - $1.81 Million
100,123 Added 400.49%
125,123 $1.7 Million
Q1 2021

May 18, 2021

BUY
$15.31 - $26.52 $217,968 - $377,565
14,237 Added 132.28%
25,000 $405,000
Q4 2020

Feb 16, 2021

BUY
$16.84 - $27.59 $181,248 - $296,951
10,763 New
10,763 $286,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $195M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.